Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome

Relative overall survival (OS) estimates reported in the MAVORIC trial are potentially confounded by a high proportion of patients randomized to vorinostat switching to mogamulizumab; furthermore, vorinostat is not used in clinical practice in the UK. Three methods were considered for crossover adju...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative effectiveness research 2022-08, Vol.11 (11), p.805-813
Main Authors: Hawkins, Neil, Muszbek, Noemi, Evans, Rachel, Dequen-O'Byrne, Pascale, Jones, Trefor, McNamara, Linda
Format: Article
Language:English
Subjects:
cutaneous T-cell lymphoma
mycosis fungoides
real-world evidence
Sézary syndrome
treatment crossover
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Relative overall survival (OS) estimates reported in the MAVORIC trial are potentially confounded by a high proportion of patients randomized to vorinostat switching to mogamulizumab; furthermore, vorinostat is not used in clinical practice in the UK. Three methods were considered for crossover adjustment. Survival post-crossover adjustment was compared with data from the Hospital Episode Statistics (HES) to contextualize estimates. Following adjustment, the OS hazard ratio for mogamulizumab versus vorinostat was 0.42 (95% CI: 0.18, 0.98) using the method considered most appropriate based on an assessment of assumptions and comparison with HES. OS of mogamulizumab relative to vorinostat may be underestimated in MAVORIC due to the presence of crossover. The HES database was used to validate this adjustment. The MAVORIC trial compares mogamulizumab with vorinostat in patients with mycosis fungoides and Sézary syndrome. Survival was confounded by 73% of vorinostat patients switching to mogamulizumab. After switching adjustment, the results suggested mogamulizumab improved overall survival.
ISSN:2042-6305
2042-6313
DOI:10.2217/cer-2022-0070